Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany. 27. Juli 2015 Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Meinerz, Reichert, D., Forstbauer, H., Keller, M., Frank, M., Klawitter, S., Kiewitz, C., Mueller, M., Meinerz, W., 2015. Annual Meeting ESGO (Society of Gynaecological Oncology) (0919). Piaza: Non-interventional Study on Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMML (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder). Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Neidig, C., Teichmann, B., Harde, J., Trarbach, T., 2015. Oncol Res Treat 38 (suppl.5)(P235), 70. doi:10.1159/000439070… Weiterlesen First interim analysis of OTILIA, a large German non-interventional study evaluating bevacizumab-containing therapy in patients with ovarian cancer. Mustea, A., Mahner, S., Oskay-Oezcelik, G., Wimberger, P., Jungberg, S., Reichert, D., Forstbauer, H., Keller, M., Richter, R., Frank, M., Klawitter, S., Kiewitz, C., Müller,… Weiterlesen